Clinical trial NCT04109482: Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.
Official title: A Phase 1/2, Open Label, Multicenter Trial to Assess the Safety and Efficacy of MB-102 in Patients With Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Keywords: CD123 CAR-T
BPDCN
Blastic plasmacytoid dendritic cell neoplasm
Lead sponsor: Mustang Bio
Sponsor class: INDUSTRY
First posted: 2019-09-30
Enrollment: 3
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A phase 1/2 study to assess the safety and efficacy of MB-102 in patients with relapsed or refractory BPDCN

Detailed description: The Phase 1 portion of the study will determine the maximum tolerated dose of MB-102.

The Phase 2 portion of the trial will evaluate the efficacy of MB-102 in relapsed or refractory BPDCN.

Eligibility criteria: Inclusion Criteria:

Blastic Plasmacytoid Dendritic Cell Neoplasm

1. Patients with a diagnosis of BPDCN according to WHO classification (Arber et al., 2016) confirmed by hematopathology and histological/cytological evidence of BPDCN in the peripheral blood, bone marrow, spleen, lymph nodes, skin and/or other sites who have failed one prior therapy.

   General Inclusion Criteria
2. Male and female patients ≥ 18 years of age at the time of consent.
3. Written informed consent in accordance with federal, local, and institutional guidelines.
4. Must be able to adhere to the study visit schedule and other protocol requirements.
5. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
6. Meet the following laboratory criteria:

   * Absolute lymphocyte count (ALC) \> 100/mm3
   * ALT/SGPT and AST/SGOT \< 2.5x the upper limit of normal (ULN) unless due to underlying disease state
   * Calculated creatinine clearance ≥ 45.0 mL/min as estimated by Cockcroft Gault and dialysis independent
   * Total bilirubin ≤ 3.0 mg/dL

     * Patients with Gilbert's Syndrome must have a total bilirubin \< 5.0 mg/dL.
   * Serum albumin ≥ 3.2 g/dL
7. Cardiac ejection fraction ≥ 45%, with no evidence of pericardial effusion as determined by an echocardiogram (ECHO) or if not available, a multigated acquisition scan (MUGA).
8. Females participants of childbearing potential must have a negative serum test.
9. Patients must agree to use a highly effective method of contraception if procreative potential exists from the start of the study until one year after the completion of lymphodepletion for females and 4 months after completion of lymphodepletion for males.
10. Patients with a previously treated malignancy if treatment of that malignancy was completed greater than 2 years before screening and the patient has no evidence of disease at the time of screening.
11. Patients who have previously undergone allogenic or autologous bone marrow transplants are allowed.
12. Centrally confirmed CD-123 positivity on the bone marrow, or for patients without bone marrow involvement local pathology assessments within 28 days from Screening, showing evidence of CD-123 positivity of skin/lymph node biopsy.

Exclusion Criteria:

1. Patients with a corticosteroid dependence on doses greater than physiological replacement i.e., prednisone no more than 7.5 mg/day or hydrocortisone less than 12mg/m2/day.
2. Contraindication or hypersensitivity to fludarabine or cyclophosphamide.
3. Hypersensitivity or known history of allergic reactions attributed to tocilizumab, Cetuximab, or other anti-EGFR -monoclonal antibodies.
4. Immunotherapy treatments within 28 days prior to leukapheresis.
5. Previous treatment with anti-CD123 CAR-T treatment.

   * Previous treatment with non-CAR-T anti-CD123 agents is allowed e.g. tagraxofusp-erzs.
6. Previous treatment with any other antileukemic or investigational agent within 7 days of leukapheresis.

   * Hydroxyurea is allowed up to 3 days prior to leukapheresis.
7. Patients with history or active seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease or any autoimmune disease with CNS involvement.
8. Patients with known CNS leukemic involvement that are refractory to intrathecal chemotherapy and/or cranio-spinal radiation that have NOT been effectively treated to complete remission (defined as \< 5 WBC/mm3 and no blasts in CSF).
9. Patients with active Graft versus Host Disease (GVHD).
10. Acute active infection

    * Patients being administered prophylactic antibiotics, antivirals, or antifungals are permitted.
11. Patients who have any form of primary immunodeficiency, such as severe combined immunodeficiency disease, human immunodeficiency virus (HIV), or acquired immune deficiency syndrome (AIDS).
12. Active infection with hepatitis B or C.
13. Patients requiring supplemental oxygen or mechanical ventilation or oxygen saturation \< 92% on room air.

    * Patients with an oxygen saturation \< 92%, a pulmonary function test with a result of Diffusing capacity of the lungs for carbon monoxide (DLCO) of ≥ 40% of predicted and a forced expiratory volume in one second (FEV1) \> 45% predicted will be accepted.
14. Patients with decompensated hepatic cirrhosis/liver failure.
15. Pregnant or lactating females.
16. Any other clinically significant medical disease or condition that, in the investigator's opinion, may interfere with protocol adherence or a patient's ability to give informed consent.

Primary outcomes:
measure: Phase 1: Safety and Tolerability as measured by the number of patients with treatment related adverse events
timeFrame: 28 Days
measure: Phase 1: Maximum Tolerated Dose (MTD) and recommended Phase 2 dose
timeFrame: 28 Days
measure: Phase 2: Response Rate of patients with BPDCN
timeFrame: up to 3 years
Secondary outcomes:
measure: Phase 2: BPDCN - DOR
timeFrame: up to 3 years
measure: Phase 2: BPDCN - PFS
timeFrame: up to 3 years
measure: Phase 2: BPDCN - OS
timeFrame: up to 3 years
measure: Phase 2: BPDCN - MRD
timeFrame: up to 3 years
measure: Phase 2 - Adverse events
timeFrame: up to 3 years
measure: Phase 2 -Change from Baseline in the European Organization for Research and Treatment (EORTC) QLQ-C 30 Version 3.0.
timeFrame: up to 3 years
measure: Phase 2 - Change from Baseline in the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) Version 4.0.
timeFrame: up to 3 years
measure: Phase 2 - Number of patients showing evidence of replication competent lentivirus
timeFrame: up to 3 years
Other outcomes:
Locations:
city: Duarte
country: United States
facility: City of Hope Medical Center
state: California
city: Boston
country: United States
facility: Dana-Farber Cancer Institute
state: Massachusetts
city: Durham
country: United States
facility: Duke University
state: North Carolina
city: Houston
country: United States
facility: MD Anderson Cancer Center
state: Texas
Study officials:
affiliation: City of Hope Medical Center
name: Lihua E Budde, MD
role: PRINCIPAL_INVESTIGATOR
References: